Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C

Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals

(2015) Rebecca Cope et al.   AIDS PATIENT CARE AND STDS

Prevalence of Drug–Drug Interactions upon Addition of Simeprevir- or Sofosbuvir-Containing Treatment to Medication Profiles of Patients with HIV and Hepatitis C Coinfection

(2015) Nimish Patel et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies

(2015) K. Deterding et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and Dasabuvir

(2015) P. Badri et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir

(2015) Prajakta S. Badri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment

(2015) Tushar Garimella et al.   ANTIVIRAL THERAPY

The Concise Guide to PHARMACOLOGY 2015/16: Transporters

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

(2015) Stephen PH Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects

(2015) Marc Bifano et al.   CLINICAL DRUG INVESTIGATION

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir

(2015) Sivi Ouwerkerk-Mahadevan et al.   CLINICAL PHARMACOKINETICS

Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

(2015) Brian J. Kirby et al.   CLINICAL PHARMACOKINETICS

Drug interactions with new hepatitis C oral drugs

(2015) Vincent Soriano et al.   Expert Opinion on Drug Metabolism & Toxicology

Interaction Between Amiodarone and Sofosbuvir-based Treatment for Hepatitis C Virus Infection: Potential Mechanisms and Lessons to be Learned

(2015) David J. Back et al.   GASTROENTEROLOGY

The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related Child's Class A Cirrhosis

(2015) Brian L. Pearlman et al.   GASTROENTEROLOGY

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

(2015) Michael Charlton et al.   GASTROENTEROLOGY

A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection

(2015) Travis B. Dick et al.   HEPATOLOGY

Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update

(2015) Jose M. Miro et al.   JOURNAL OF HEPATOLOGY

Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment

(2015) Amit Khatri et al.   JOURNAL OF HEPATOLOGY

Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease

(2015) Bhamidimarri Kalyan Ram et al.   JOURNAL OF HEPATOLOGY

Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir

(2015) Rajeev M. Menon et al.   JOURNAL OF HEPATOLOGY

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine

(2015) Jacob Lalezari et al.   JOURNAL OF HEPATOLOGY

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting

(2015) Christoph Höner zu Siederdissen et al.   LIVER INTERNATIONAL

A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease

(2015) Anna Maruyama et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

(2015) Christopher Southan et al.   NUCLEIC ACIDS RESEARCH

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients

(2015) Isabelle Poizot-Martin et al.   PLoS One

Hepatitis C virus and liver transplantation: where do we stand?

(2015) Patrizia Burra et al.   TRANSPLANT INTERNATIONAL

Evaluation of the Pharmacokinetics and Renal Excretion of Simeprevir in Subjects with Renal Impairment

(2015) Sivi Ouwerkerk-Mahadevan et al.   Drugs in research & development

The Rapid Evolution of Treatment Strategies for Hepatitis C

(2014) Andrew J Muir   AMERICAN JOURNAL OF GASTROENTEROLOGY

Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides

(2014) Tomomi Furihata et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Advances in Therapy for HIV/Hepatitis C Virus-Coinfected Patients in the Liver Transplant Setting

(2014) I. Campos-Varela et al.   CLINICAL INFECTIOUS DISEASES

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations

(2014) Clara T. M. M. de Kanter et al.   CLINICAL PHARMACOKINETICS

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: Potent antiviral activity but no clinical benefit if treatment is given late

(2014) Adriano M. Pellicelli et al.   DIGESTIVE AND LIVER DISEASE

Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?

(2014) Sarah Talavera Pons et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database

(2014) Julie C. Lauffenburger et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-Uninfected female subjects

(2014) P. German et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study

(2014) Tomohiro Tanaka et al.   Journal of Hepato-Biliary-Pancreatic Sciences

Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation

(2014) Martina Gambato et al.   JOURNAL OF HEPATOLOGY

Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals

(2014) Audrey Coilly et al.   LIVER INTERNATIONAL

Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients

(2014) Joy Peter et al.   LIVER INTERNATIONAL

Fluctuations in the concentration/dose ratio of calcineurin inhibitors after simeprevir administration in patients with recurrent hepatitis C after liver transplantation

(2014) Yoshihide Ueda et al.   TRANSPLANT INTERNATIONAL

The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C

(2013) B. Maasoumy et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C

(2013) R. J. Fontana et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.

(2013) Marc Bifano et al.   ANTIVIRAL THERAPY

Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate

(2013) Marc Bifano et al.   ANTIVIRAL THERAPY

Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection

(2013) Drosos E. Karageorgopoulos et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Drug–drug interactions during antiviral therapy for chronic hepatitis C

(2013) Jennifer J. Kiser et al.   Nature Reviews Gastroenterology & Hepatology

Pharmacokinetics of new oral hepatitis C antiviral drugs

(2012) Eugenia Vispo et al.   Expert Opinion on Drug Metabolism & Toxicology

Mécanismes des interactions médicamenteuses d’origine pharmacocinétique

(2009) D. Levêque et al.   REVUE DE MEDECINE INTERNE

The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters

(2009) Olena Kis et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Induction Effects of Ritonavir: Implications for Drug Interactions

(2008) Michelle M Foisy et al.   ANNALS OF PHARMACOTHERAPY